Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (SHE:002399)

Revenue by Segment

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2023	FY 2022	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015
Period Ending	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015
Active Pharmaceutical Ingredient (API)	3.39B	3.44B	2.67B	2.72B	2.70B
Active Pharmaceutical Ingredient (API) Growth	-1.72%	28.84%	-1.77%	0.77%	-
Intersegment offset	-6.72B	-5.88B	-	-	-
Others	415.03M	448.25M	191.12M	191.89M	310.32M
Others Growth	-7.41%	134.54%	-0.40%	-38.16%	-
CDMO	1.03B	968.26M	1.08B	813.10M	797.39M
CDMO Growth	6.78%	-10.68%	33.32%	1.97%	-
Preparations	7.14B	6.45B	3.21B	2.64B	1.52B
Preparations Growth	10.80%	100.85%	21.69%	73.20%	-
Total	5.26B	5.43B	7.16B	6.37B	5.33B
Total Growth	-3.17%	-24.14%	12.48%	19.38%	-

Revenue by Geography

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2023	FY 2022	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015
Period Ending	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015
Foreign	-	-	6.51B	5.81B	4.80B
Foreign Growth	-	-	12.09%	20.96%	13.98%
China	-	-	649.85M	557.63M	530.90M
China Growth	-	-	16.54%	5.04%	28.77%
Hong Kong	7.20M	18.10M	-	-	-
Hong Kong Growth	-60.19%	-	-	-	-
United States of America	1.43B	1.28B	-	-	-
United States of America Growth	11.96%	-	-	-	-
Europe	2.37B	2.62B	-	-	-
Europe Growth	-9.28%	-	-	-	-
Mainland China	339.16M	397.84M	-	-	-
Mainland China Growth	-14.75%	-	-	-	-
Other Countries/Regions	1.11B	1.12B	-	-	-
Other Countries/Regions Growth	-1.11%	-	-	-	-
Total	5.26B	5.43B	7.16B	6.37B	5.33B
Total Growth	-3.17%	-24.14%	12.48%	19.38%	15.30%

Source: S&P Global Market Intelligence.